Selected Publications

---

Asterisk (*) indicates author was a UT Dallas student working with Dr. Le Prell

2023

Le Prell, C. G.  (2023). Preclinical prospects of investigational agents for hearing loss treatment, Expert Opinion on Investigational Drugs, 32(8):685-692; doi: 10.1080/13543784.2023.2253141.

Zaccardi, T. A.*, Portnuff, C. D. F., and Le Prell, C. G.  (2023). Preliminary investigation of perceived sound quality for high-fidelity premolded hearing protection devices, Medical Problems of Performing Artists, 38(1):63-70, doi: 10.21091/mppa.2023.1008.

Grinn, S.K.*, and Le Prell, C. G.  (2022). Evaluation of hidden hearing loss in normal hearing firearm users. Frontiers in Neuroscience, 16:1005148. doi:10.3389/fnins.2022.1005148.

2022

Grinn, S.K.*, and Le Prell, C. G.  (2022). Evaluation of hidden hearing loss in normal hearing firearm users. Frontiers in Neuroscience, 16:1005148. doi:10.3389/fnins.2022.1005148.

Zaccardi, T.*, Portnuff, C., and Le Prell, C.G.  (2022). Verification of attenuation for premolded hearing protection devices designed for music, Medical Problems of Performing Artists, 37(2): 78-88; doi: 10.21091/mppa.2022.2013.

Le Prell, C. G. (2022). Prevention of noise-induced hearing loss using antioxidants and other drug agents: previous trial outcomes should inform future trial design. Antioxidants and Redox Signaling, 36(16-18): 1171-1201, doi: 10.1089/ars.2021.0166.

2021

Le Prell, C. G.  (2021). Investigational medicinal products for the inner ear: Review of clinical trial characteristics in ClinicalTrials.gov.  Journal of the American Academy of Audiology, 32(10): 670-694, doi: 10.1055/s-0041-1735522.

Grinn, S.*, and Le Prell, C. G. (2021). Modeling individual noise-induced hearing loss risk with proxy metrics of external ear amplification, Journal of the Acoustical Society of America, 149(6), 3975-3987; https://doi.org/10.1121/10.0005061.